Consolidated Portfolio Review Corp Purchases Shares of 64,883 Ekso Bionics Holdings, Inc. $EKSO

Consolidated Portfolio Review Corp acquired a new position in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 64,883 shares of the company’s stock, valued at approximately $333,000.

Insiders Place Their Bets

In other Ekso Bionics news, major shareholder Daniel Asher acquired 15,540 shares of the stock in a transaction on Thursday, February 19th. The shares were bought at an average cost of $12.30 per share, with a total value of $191,142.00. Following the transaction, the insider owned 270,432 shares of the company’s stock, valued at approximately $3,326,313.60. This trade represents a 6.10% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 6.00% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on EKSO shares. HC Wainwright downgraded shares of Ekso Bionics from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 31st. Weiss Ratings reissued a “sell (e+)” rating on shares of Ekso Bionics in a research report on Monday, December 22nd. Finally, Wall Street Zen upgraded shares of Ekso Bionics to a “hold” rating in a research note on Saturday, December 13th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus target price of $6.00.

Ekso Bionics Stock Performance

Shares of EKSO opened at $11.38 on Friday. The company’s 50 day simple moving average is $9.35 and its 200-day simple moving average is $6.27. The firm has a market cap of $40.51 million, a PE ratio of -2.21 and a beta of 0.79. Ekso Bionics Holdings, Inc. has a 12-month low of $2.73 and a 12-month high of $13.27. The company has a current ratio of 1.63, a quick ratio of 1.07 and a debt-to-equity ratio of 0.09.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.